Drug may reverse Down's cognitive deficit

Cognitive deficits in adult patients with Down's syndrome could be reversed by treatment targeting the noradrenaline system, a US study has suggested.

It found that administration of a pro-noradrenaline drug, called L-DOPS, reversed behavioural signs of learning deficits in a mouse model of the condition.

The drug was tested in mice with three copies of mouse chromosome 16. These mice have contextual learning defects thought to mimic those seen in people with Down's syndrome.

Mice given the drug were found to perform equivalently well to a group of control mice without the chromosomal disorder on a nest-building task designed to test their contextual learning ability.

The researchers concluded that drug treatment to enhance noradrenaline transmission could be used to improve learning and memory in patients with Down's syndrome.

Lead researcher Dr William Mobley, chair of the department of neurosciences at the University of California, San Diego School of Medicine said: 'Giving the pro-noradrenaline drug to the mice rescued cognitive behaviours in a dramatic way.

'The possibility is very real that such a therapy, if proven safe, would be effective in treating dementia in later-stage Down's syndrome patients.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Pension tax solution for judges shows government could do more for doctors, says BMA

Pension tax solution for judges shows government could do more for doctors, says BMA

Government plans to 'effectively exempt judges from pension tax' show the government...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Second-phase COVID-19 vaccine rollout maintains prioritisation by age

Second-phase COVID-19 vaccine rollout maintains prioritisation by age

The Joint Committee on Vaccination and Immunisation (JCVI) has published advice on...

PCNs paid £70m for first-wave COVID-19 jab campaign as NHS plots next phase of rollout

PCNs paid £70m for first-wave COVID-19 jab campaign as NHS plots next phase of rollout

Primary care network (PCN) COVID-19 vaccination sites have been paid £70m this month...

London GP personally calling at-risk patients to boost COVID-19 vaccine uptake

London GP personally calling at-risk patients to boost COVID-19 vaccine uptake

London GP Dr Farzana Hussain is personally telephoning scores of patients who have...

Half of patients with possible cancer symptoms avoided contacting GP in first wave

Half of patients with possible cancer symptoms avoided contacting GP in first wave

Almost half of people who experienced potential cancer symptoms in the first wave...